Etretinate Therapy in Generalized Pustular Psoriasis (Zumbusch Type)

Wolska, Hanna; Jabłońska, S.; Langner, Andrzej; Frączykowska, M.

doi:10.1159/000249441

Cited by 20 publications

(21 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comments: In general, the dose of etretinate for the treatment of GPP starts with 0.5–1.0 mg/kg per day and should be adjusted according to symptoms. Many case reports and case series reports showed the efficacy of etretinate in GPP . However, RCT have not been performed to compare the efficacy of etretinate with that of other drugs or placebo.…”

Section: Chapter V: Strength Of Recommendations and Comments For Eachmentioning

confidence: 99%

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Fujita

Terada

Hayama

et al. 2018

The Journal of Dermatology

192

456

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a rare disease characterized by recurrent fever and systemic flushing accompanied by extensive sterile pustules. The committee of the guidelines was founded as a collaborative project between the Japanese Dermatological Association and the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labour, and Welfare Research Project on Overcoming Intractable Diseases. The aim of the guidelines was to provide current information to aid in the treatment of patients with GPP in Japan. Its contents include the diagnostic and severity classification criteria for GPP, its pathogenesis, and recommendations for the treatment of GPP. Since there are few clinical trial data with high levels of evidence for this rare disease, recommendations by the committee are described in the present guidelines.

show abstract

Section: Chapter V: Strength Of Recommendations and Comments For Eachmentioning

confidence: 99%

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Fujita

Terada

Hayama

et al. 2018

The Journal of Dermatology

192

456

View full text Add to dashboard Cite

show abstract

“…C-reactive protein is a sensitive marker of inflammation, synthesized and secreted by the liver. Its production is stimulated by interleukin-6, involved in the pathogenesis of many diseases, including psoriasis [8]. C-reactive protein seems to be a good marker of inflammation in psoriasis due to linkage of cytokines responsible for inflammation of the skin.…”

Section: Discussionmentioning

confidence: 99%

“…Many studies suggest that proinflammatory cytokines may affect the development of atherosclerotic lesions in blood vessels and insulin resistance [4,7]. Psoriasis is a chronic inflammatory skin disease characterized by immunological abnormalities and increased release of inflammatory mediators, including tumour necrosis factor α (TNF-α), interleukin-1 (IL-1), interleukin-8 (IL-8) [8], which simultaneously stimulates the development of metabolic disorders, e.g. obesity.…”

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome in psoriasis

Szponar-Bojda¹,

Krasowska²,

Pietrzak³

et al. 2012

pdia

View full text Add to dashboard Cite

A b s t r a c t I In nt tr ro od du uc ct ti io on n: : Recent years' studies have revealed a link between the metabolic syndrome and psoriasis. The common elements of pathogenesis of both diseases, primarily associated with severe inflammation, may be responsible for an increased incidence of metabolic syndrome components in psoriasis patients. A Ai im m: : To evaluate the prevalence of selected risk factors for the metabolic syndrome in patients with psoriasis and possible involvement of these factors in the severity of psoriasis. M Ma at te er ri ia al l a an nd d m me et th ho od ds s: : The study included 117 adult psoriatic patients compared with a control group. The severity of psoriasis was evaluated using the PASI and mNAPSI score. Basic laboratory tests were performed. The body mass index (BMI), De Ritis ratio and blood pressure were determined for each patient. R Re es su ul lt ts s: : In the psoriasis group, excess body weight and abnormal values of BMI were significantly more frequent. Body mass index and body weight were significantly higher in patients with the calculated De Ritis ratio than in other subjects. The levels of erythrocyte sedimentation rate and C-reactive protein were significantly higher in the psoriasis group and positively correlated with BMI. Compared with controls, patients with psoriasis had significantly higher values of systolic and diastolic blood pressure, with no correlation with the severity of psoriasis evaluated using the PASI and mNAPSI score. C Co on nc cl lu us si io on ns s: : The results obtained in our study indicate that psoriatic patients appear to be at a higher risk of the metabolic disorders such as hypertension, obesity, liver dysfunction, increased inflammatory parameters than healthy subjects, irrespective of the full manifestation of the metabolic syndrome. We suggest that patients with psoriasis should be routinely screened for the presence of the above-mentioned disorders. K Ke ey y w wo or rd ds s: : psoriasis, metabolic syndrome, De Ritis ratio, C-reactive protein, hypertension.

show abstract

“…Acitretin is one of the treatments of choice in pustular psoriasis. There are case series of treatment of GPP with etretinate . Wolska et al .…”

Section: Efficacy As Monotherapymentioning

confidence: 99%

Acitretin in psoriasis: an evolving scenario

Dogra

Yadav

2014

Int J Dermatology

View full text Add to dashboard Cite

Acitretin, an active metabolite of etretinate, is the most widely used systemic retinoid in the treatment of psoriasis. There are several unique characteristics of this drug, which set it apart from other options in the therapeutic armamentarium of psoriasis. It is highly efficacious as monotherapy in some specific clinical subtypes of psoriasis. It has dose-sparing effects when used as combination therapy with conventional systemic drugs as well as the biologics. It is a good option for long-term maintenance therapy. Side effects are common but usually mild and can be managed by its proper dosing and monitoring. With appropriate patient selection, gradual dose escalation, and patient counseling, we can deliver good results in psoriasis with this useful drug. This review gives a comprehensive recount of acitretin use in the present era of biologics in psoriasis.

show abstract

Etretinate Therapy in Generalized Pustular Psoriasis (Zumbusch Type)

Cited by 20 publications

References 5 publications

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Metabolic syndrome in psoriasis

Acitretin in psoriasis: an evolving scenario

Contact Info

Product

Resources

About